The epidemiology of meningococcal disease and the impact of vaccines

Expert Review of Vaccines

Volumn 9, Issue 3, 2010, Pages 285-298

  Khatami, Ameneh ^a   Pollard, Andrew J ^b  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Epidemiology; Immunization; Meningitis; Meningococcal disease; Vaccine

Indexed keywords

BACTERIUM ANTIBODY; DIPHTHERIA TOXOID CRM197; MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; TETANUS TOXOID;

AFRICA; ANTIBODY DETECTION; ANTIBODY RESPONSE; ASIA; ASPLENIA; AUSTRALIA; BACTERIAL COLONIZATION; BACTERIUM ISOLATE; BLOOD GROUP TYPING; CENTRAL AMERICA; COUGHING; CROWDING; DISEASE CONTROL; DISEASE TRANSMISSION; ENVIRONMENTAL FACTOR; ENZYME IMMUNOASSAY; EPIDEMIC; EUROPE; HAEMOPHILUS INFLUENZAE TYPE B; HERD IMMUNITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INCIDENCE; MENINGOCOCCOSIS; MIDDLE EAST; NEISSERIA MENINGITIDIS; NEW ZEALAND; NONHUMAN; PANDEMIC; PHENOTYPE; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; REVIEW; RISK FACTOR; SOCIAL STATUS; SOUTH AMERICA; UNITED STATES; URTICA DIOICA; VACCINATION; VIRUS STRAIN; VIRUS TRANSMISSION;

AFRICA; AMERICAS; ASIA; ENDEMIC DISEASES; EUROPE; HUMANS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS;

EID: 77949445223     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.3     Document Type: Review

References (161)

1. Harrison LH. Prospects for vaccine prevention of meningococcal infection. Clin. Microbiol. Rev. 19, 142-164 (2006).
2. Rosenstein N, Perkins B, Stephens D, Popovic T, Hughes J. Meningococcal disease. N. Engl. J. Med. 344, 1378-1388 (2001).
3. Kvalsvig AJ, Unsworth DJ. The immunopathogenesis of meningococcal disease. J. Clin. Pathol. 56, 417-422 (2003).
4. Wilder-Smith A. Meningococcal vaccine in travelers. Curr. Opin Infect. Dis. 20, 454-460 (2007).
5. World Health Organization. Epidemics of meningococcal disease, African meningitis belt, 2001. Wkly Epidemiol. Rec. 37, 282-288 (2001).
6. Wilder-Smith A, Memish Z. Meningococcal disease and travel. Int. J. Antimicrob. Agents 21, 102-106 (2003).
7. Pollard AJ. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr. Infect. Dis. J. 23, S274-S279 (2004).
8. Baltimore RS. Recent trends in meningococcal epidemiology and current vaccine recommendations. Curr. Opin. Pediatr. 18, 58-63 (2006).
9. Russell JE, Urwin R, Gray SJ, Fox AJ, Feavers IM, Maiden MCJ. Molecular epidemiology of meningococcal disease in England and Wales 1975-1995, before the introduction of serogroup C conjugate vaccines. Microbiology 154, 1170-1177 (2008).
10. Urwin R, Maiden MC. Multi-locus sequence typing: a tool for global epidemiology. Trends Microbiol. 11, 479-487 (2003).
11. Yazdankhah SP, Kriz P, Tzanakaki G et al. Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitides from the Czech Republic, Greece, and Norway. J. Clin Microbiol. 42, 5146-5153 (2004).
12. Urwin R, Russell JE, Thompson EA, Holmes EC, Feavers IM, Maiden MC. Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect. Immun. 72, 5955-5962 (2004).
13. Jelfs J, Munro R. Epidemiology of meningococcal disease in Australia. J. Paediatr. Child Health 37, S3-S6 (2001).
14. Brehony C, Jolley KA, Maiden MCJ. Multilocus sequence typing for global surveillance of meningococcal disease. FEMS Microbiol. Rev. 31, 15-26 (2007).
15. Nicolas P, Norheim G, Garnotel E, Djibo S, Caugant DA. Molecular epidemiology of Neisseria meningitides isolated in the African Meningitis Belt between 1988 and 2003 shows dominance of sequence type 5 (ST-5) and ST-11 complexes. J. Clin. Microbiol. 43, 5129-5135 (2005).
16. Mayer LW, Reeves MW, Al-Hamdan N et al. Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electophoretic type-37 complex. J. Infect. Dis. 185, 1596-1605 (2002).
17. Aguilera, JF, Perrocheau A, Meffre A, Hahne S. Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000. Emerg. Infect. Dis. 8, 761-767 (2002).
18. Caugant DA, Tzanakaki G, Kriz P. Lessons from meningococcal carriage studies. FEMS Microbiol. Rev. 31, 5263 (2007).
19. Claus H, Maiden MC, Wilson DJ et al. Genetic analysis of meningococci carried by children and young adults. J. Infect. Dis. 191, 1263-1271 (2005).
20. Ruggeberg JU, Pollard AJ. Meningococcal vaccines. Paediatr. Drugs 6, 251-266 (2004).
21. Neal KR, Nguyen-Van-Tam JS, Jeffrey N et al. Changing carriage rate of Neisseria meningitidis among university students during the first week of term: cross sectional study. Br. Med. J. 320, 846-849 (2000).
22. Ala'Aldeen DA, Neal KR, Ait-Tahar K et al. Dynamics of meningococcal long-term carriage among university students and their implications for mass vaccination. J. Clin. Microbiol. 38, 2311-2316 (2000).
23. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. Development of natural immunity. J. Exp. Med. 129, 1327-1348 (1969).
24. Robinson K, Neal KR, Howard C et al. Characterization of humoral and cellular immune responses elicited by meningococcal carriage. Infect. Immun. 70, 1301-1309 (2002).
25. Jordens JZ, Williams JN, Jones GR, Christodoulides M, Heckels JE. Development of immunity to serogroup B meningococci during carriage of Neisseria meningitidis in a cohort of university students. Infect. Immun. 72, 6503-6510 (2004).
26. Raghunathan PL, Jones JD, Tiendrebeogo SR et al. Predictors of immunity after a major serogroup W-135 meningococcal disease epidemic, Burkina Faso, 2002. J. Infect. Dis. 193, 607-616 (2006).
27. Thorburn K, Baines P, Thomson A, Hart CA. Mortality in severe meningococcal disease. Arch. Dis. Child. 85, 382-385 (2001).
28. Cartwright K, Strang J, Reilly S, White D. Mortality in meningococcal disease. Br. Med. J. 304, 116 (1992).
29. Gray SJ, Trotter CL, Ramsay ME et al. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J. Med. Microbiol. 55, 887-896 (2006).
30. Healy CM, Butler KM, Smith EO et al. Influence of serogroup on the presentation, course, and outcome of invasive meningococcal disease in children in the Republic of Ireland, 1995-2000. Clin. Infect. Dis. 34, 1323-1330 (2002).
31. Emonts M, Hazelzet JA, de Groot R, Hermans PW. Host genetic determinants of Neisseria meningitidis infections. Lancet Infect. Dis. 3, 565-577 (2003).
32. Figueroa JE, Densen P. Infectious diseases associated with complement deficiencies. Clin. Microbiol. Rev. 4, 359-395 (1991).
33. Kuipers S, Aerts PC, Cluysenaer OJ et al. A case of familial meningococcal disease due to deficiency in mannose-binding lectin (MBL). Adv. Exp. Med. Biol. 531, 351-355 (2003).
34. Stephens DS, Hajjeh RA, Baughman WS, Harvey RS, Wenger JD, Farley MM. Sporadic meningococcal disease in adults: results of a 5-year population-based study. Ann. Intern. Med. 123, 937-940 (1995).
35. Rosenstein NE, Perkins BA, Stephens DS et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J. Infect. Dis. 180, 1894-1901 (1999).
36. Cartwright KA, Jones DM, Smith AJ, Stuart JM, Kaczmarski E, Palmer SR. Influenza A and meningococcal disease. Lancet 338, 554-557 (1991).
37. Moore PS, Hierholzer J, DeWitt W et al. Respiratory viruses and mycoplasma as cofactors for epidemic group A meningococcal meningitis. JAMA 264, 1271-1275 (1990).
38. Cookson ST, Corrales JL, Lotero JO et al. Disco fever: epidemic meningococcal disease in northeastern Argentina associated with disco patronage. J. Infect. Dis. 178, 266-269 (1998).
39. Fischer M, Hedberg K, Cardosi P et al. Tobacco smoke as a risk factor for meningococcal disease. Pediatr. Infect. Dis. J. 16, 979-983 (1997).
40. Imrey PB, Jackson LA, Ludwinski PH et al. Meningococcal carriage, alcohol consumption, and campus bar patronage in a serogroup C meningococcal disease outbreak. J. Clin. Microbiol. 33, 3133-3137 (1995).
41. Bruce MG, Rosenstein NE, Capparella JM, Shutt KA, Perkins BA, Collins M. Risk factors for meningococcal disease in college students. JAMA 286, 688-693 (2001).
42. Teyssou R, Muros-Le Rouzic E. Meningitis epidemics in Africa: a brief overview. Vaccine 25S, A3-A7 (2007).
43. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report: Emerging Infections Program Network. Neisseria meningitides, 2008. Provisional Report (2008).
44. Centers for Disease Control and Prevention. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm. Rep. 56(31), 794-795 (2007).
45. Caro JJ, Möller J, Getsios D et al. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation. BMC Public Health 7, 130-141 (2007).
46. Diermayer M, Hedberg K, Hoesly F et al. Epidemic serogroup B meningococcal disease in Oregon: the evolving epidemiology of the ET-5 strain. JAMA 281, 1493-1497 (1999).
47. Raghunathan PL, Bernhardt SA, Rosenstein NE. Opportunities for control of meningococcal disease in the United States. Ann. Rev. Med. 55, 333-353 (2004).
48. Brundage JF, Ryan MA, Feighner BH et al. Meningococcal disease among United States military service members in relation to routine uses of vaccines with different serogroup-specific components, 1964-1998. Clin. Infect. Dis. 35, 1376-1381 (2002).
49. Harrison LH, Jolley KA, Shutt KA et al. Antigenic shift and increased incidence of meningococcal disease. J. Infect. Dis. 193, 1266-1274 (2006).
50. Stephens DS. Conquering the meningococcus. FEMS Microbiol. Rev. 31, 3-14 (2007).
51. Trotter CL, Chandra M, Cano R et al. A surveillance network for meningococcal disease in Europe. FEMS Microbiol. Rev. 31, 27-36 (2007).
52. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20, S58-S67 (2001).
53. Wylie PA, Stevens D, Drake W 3rd, Stuart J, Cartwright K. Epidemiology and clinical management of meningococcal disease in west Gloucestershire: retrospective, population based study. Br. Med. J. 315, 774-779 (1997).
54. Holst J, Feiring B, Naess LM et al. The concept of 'tailor-made', protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine 23, 2202-2205 (2005).
55. Law DK, Lorange M, Ringuette L et al. Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19). J. Clin. Microbiol. 44, 2743-2749 (2006).
56. Diggle MA, Clarke SC. Increased genetic diversity of Neisseria meningitidis isolates after the introduction of meningococcal serogroup C polysaccharide conjugate vaccines. J. Clin. Microbiol. 43, 4649-4653 (2005).
57. Lennon D, Gellin B, Hood D, Voss L, Heffernan H, Thakur S. Successful intervention in a group A meningococcal outbreak in Auckland, New Zealand. Pediatr. Infect. Dis. J. 11, 617-623 (1992).
58. Patel MS, Merianos A, Hanna JN et al. Epidemic meningococcal meningitis in central Australia, 1987-1991. Med. J. Aust. 158, 336-340 (1993).
59. Thornton V, Lennon D, Rasanathan K et al. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control. Vaccine 24, 1395-1400 (2006).
60. Baker MG, Martin DR, Kieft CE, Lennon D. A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991-2000. J. Paediatr. Child Health 37, S13-S19 (2001).
61. Martin D, Lopez L. The Epidemiology of Meningococcal Disease in New Zealand in 2007. Report prepared for the Ministry of Health by the Institute of Environmental Science and Research Limited (ESR). Institute of Environmental Science and Research Ltd (2008).
62. Patel M. Meningococcal disease in Australia; looking at the past, thinking of the future. Commun. Dis. Intell. 21, 233-236 (1997).
63. Annual report of the Australian Meningococcal Surveillance Programme, 1998. Commun. Dis. Intell. 23, 317-323 (1999).
64. Jelfs J. Munro R. Epidemiology of meningococcal disease in Australia. J. Paediatr. Child Health 37, S3-S6 (2001).
65. Booy R, Jelfs J, El Bashir H, Nissen MD. Impact of meningococcal C conjugate vaccine use in Australia. Med. J. Aust. 186, 108-109 (2007).
66. Baethgen LF, Weidlich L, Moraes C et al. Epidemiology of meningococcal disease in southern Brazil from 1995 to 2003, and molecular characterization of Neisseria meningitidis using multilocus sequence typing. Trop. Med. Int. Health 13, 31-40 (2008).
67. Efron AM, Sorhouet C, Salcedo C, Abad R, Regueira M, Vazquez JA. W135 invasive meningococcal strains spreading in South America: significant increase in incidence rate in Argentina. J. Clin. Microbiol. 47, 1979-1980 (2009).
68. Sosa J, Llanes R, Guzman D, Quintana I, Flores M, Gutierrez O. Typing and susceptibility to penicillin of Neisseria meningitidis isolated from patients in Cuba (1993-1999). Mem. Inst. Oswaldo Cruz 96, 523-525 (2001).
69. Morelli G, Malorny B, Muller K et al. Clonal descent and microevolution of Neisseria meningitidis during 30 years of epidemic spread. Mol. Microbiol. 25, 1047-1064 (1997).
70. Lapeyssonnie L. La méningite cérébrospinale en Afrique. Bull. World Health Organ. 28, 1-114 (1963).
71. [No authors listed]. The risk of epidemic meningitis in Africa: a cause for concern. WHO Wkly Epidemiol. Rec. 82, 77-88 (2007).
72. Greenwood B. Manson lecture. Meningococcal meningitis in Africa. Trans. R. Soc. Trop. Med. Hyg. 93, 341-353 (1999).
73. Nicolas P, Decousset L, Riglet V, Castelli P, Stor R, Blanchet G. Clonal expansion of sequence type (ST-)5 and emergence of ST-7 in serogroup A meningococci, Africa. Emerg. Infect. Dis. 7, 849-854 (2001).
74. Campagne G, Schuchat A, Djibo S, Ousseini A, Cisse L, Chippaux JP. Epidemiology of bacterial meningitis in Niamey, Niger, 1981-1996. Bull. World Health Organ. 77, 499-508 (1999).
75. Djibo S, Nicolas P, Alonso JM et al. Outbreaks of serogroup X meningococcal meningitis in Niger 1995-2000. Trop. Med. Int. Health 8, 1118-1123 (2003).
76. Gagneux SP, Hodgson A, Smith TA et al. Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana. J. Infect. Dis. 185, 618-626 (2002).
77. Boisier P, Nicolas P, Djibo S et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin. Infect. Dis. 44, 657-663 (2007).
78. Materu S, Cox HS, Isaakidis P et al. Serogroup X in meningococcal disease, Western Kenya. Emerg. Infect. Dis. 13, 944-945 (2007).
79. Caugant DA. Population genetics and molecular epidemiology of Neisseria meningitidis. APMIS 106, 505-525 (1998).
80. Zhang X, Shao Z, Zhu Y et al. Genetic characteristics of serogroup A meningococci circulating in China, 1956-2005. Clin. Microbiol. Infect. 14, 555-561 (2008).
81. Shao Z, Li W, Ren J et al. Identification of a new Neisseria meningitidis serogroup C clone from Anhui province, China. Lancet 367, 419-423 (2006).
82. Moore PS, Harrison LH, Telzak EE, Ajello GW, Broome CV. Group A meningococcal carriage in travelers returning from Saudi Arabia. JAMA 260, 2686-2689 (1988).
83. Taha MK, Achtman M, Alonso JM et al. Serogroup W135 meningococcal disease in Hajj pilgrims. Lancet 356, 2159 (2000).
84. Wilder-Smith A, Goh KT, Barkham T, Paton NI. Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. Clin. Infect. Dis. 36, 679-683 (2003).
85. World Health Organization. Meningococcal disease in the African meningitis belt - Update 4 - 27 March 2001 - Disease Outbreak Reported. WHO Global Alert and Response (2001).
86. Jolley KA, Wilson DJ, Kriz P, McVean G, Maiden MC. The influence of mutation, recombination, population history, and selection on patterns of genetic diversity in Neisseria meningitidis. Mol. Biol. Evol. 22, 562-569 (2005).
87. Andrews TD, Gojobori T. Strong positive selection and recombination drive the antigenic variation of the PilE protein of the human pathogen Neisseria meningitidis. Genetics 166, 25-32 (2004).
88. Wilder-Smith A, Barkham TM, Chew SK, Paton NI. Absence of Neisseria meningitidis W-135 electrophoretic type 37 during the Hajj, 2002. Emerg. Infect. Dis. 9, 734-737 (2003).
89. Al-Mazrou Y, Khalil M, Borrow R et al. Serologic responses to ACYW135 polysaccharide meningococcal vaccine in Saudi children under 5 years of age. Infect. Immun. 73, 2932-2939 (2005).
90. Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus. IV: immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J. Exp. Med. 129, 1367-1384 (1969).
91. Artenstein MS, Gold R, Zimmerly JG et al. Prevention of meningococcal disease by group C polysaccharide vaccine. N. Engl. J. Med. 282, 417-420 (1970).
92. Brundage JF, Ryan MA, Feighner BH, Erdtmann FJ. Meningococcal disease among United States military service members in relation to routine uses of vaccines with different serogroup-specific components, 1964-1998. Clin. Infect. Dis. 35, 1376-1381 (2002).
93. Gold R, Lepow ML, Goldschneider I, Draper TL, Gotschlich EC. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J. Clin. Investig. 56, 1536-1547 (1975).
94. Patel M, Lee CK. Polysaccharide vaccines for preventing serogroup A meningococcal meningitis. Cochrane Database Syst. Rev. 1, CD001093 (2005).
95. De Wals P, De Serres G, Niyonsenga T. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec. JAMA 285, 177-181 (2001).
96. Khalil M, Al-Mazrou Y, Balmer P, Bramwell J, Andrews N, Borrow R. Immunogenicity of meningococcal ACYW135 polysaccharide vaccine in Saudi children 5 to 9 years of age. Clin. Diagn. Lab. Immunol. 12, 1251-1253 (2005).
97. Gold R, Lepow ML, Goldschneider I et al. Antibody responses of human infants to three doses of group A Neisseria meningitidis polysaccharide vaccine administered at two, four, and six months of age. J. Infect. Dis. 138, 731-735 (1978).
98. Committee on Infectious Diseases. Prevention and control of meningococcal disease: recommendations for use of meningococcal vaccines in pediatric patients. Pediatrics 116, 496-505 (2005).
99. Girard MP, Preziosi MP, Aguado MT, Kieny MP. A review of vaccine research and development: meningococcal disease. Vaccine 24, 4692-4700 (2006).
100. Richmond P, Kaczmarski E, Borrow R et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J. Infect. Dis. 181, 761-764 (2000).
101. Costantino P, Viti S, Podda A, Velmonte MA, Nencioni L, Rappuoli R. Development and Phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine 10, 691-698 (1992).
102. Kelly DF, Snape MD, Clutterbuck EA et al. CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells. Blood 108, 2642-2647 (2006).
103. Granoff DM, Harris SL. Protective activity of group C anticapsular antibodies elicited in two-year-olds by an investigational quadrivalent Neisseria meningitides-diphtheria toxoid conjugate vaccine. Pediatr. Infect. Dis. J. 23, 490-497 (2004).
104. Snape MD, Kelly DF, Green B, Moxon ER, Borrow R, Pollard AJ. Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr. Infect. Dis. J. 24, 128-131 (2005).
105. Maiden MCJ, Stuart JM, for the UK Meningococcal Carriage Group. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 359, 1829-1830 (2002).
106. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. Br. Med. J. 326, 365-366 (2003).
107. Zhang Q, Choo S, Everard J, Jennings R, Finn A. Mucosal immune responses to meningococcal group C conjugate and group A and C polysaccharide vaccines in adolescents. Infect. Immun. 68, 2692-2697 (2000).
108. Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria in childhood with protein- polysaccharide conjugate vaccines. Nat. Rev. Immunol. 9, 213-220 (2009).
109. Lexau CA, Lynfield R, Danila R et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294, 2043-2051 (2005).
110. Trotter CL, Ramsay ME, Kaczmarski EB. Meningococcal serogroup C vaccination in England and Wales: coverage and initial impact of the campaign. Commun. Dis. Publ. Health 5, 220-225 (2002).
111. Maiden MC, Ibarz-Pavon AB, Urwin R et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J. Infect. Dis. 197, 737-743 (2008).
112. Gjini AB, Stuart JM, Lawlor DA et al. Changing epidemiology of bacterial meningitis among adults in England and Wales 1991-2002. Epidemiol. Infect. 134, 567-569 (2006).
113. Bogaert D, Hermans PWM, Boelens H et al. Epidemiology of nasopharyngeal carriage of Neisseria meningitides in healthy Dutch children. Clin. Infect. Dis. 40, 899-902 (2005).
114. de Greeff SC, de Melker HE, Spanjaard L, Schouls LM, van Derende A. Protection from routine vaccination at 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr. Infect. Dis. J. 25, 79-80 (2006).
115. Kafetzis DA, Stamboulidis KN, Tzanakaki G et al. Meningococcal group C disease in Greece. Clin. Microbiol. Infect. 13, 550-552 (2007).
116. Pelton SI. Prevention of invasive meningococcal disease in the United States. Pediatr. Infect. Dis. J. 28, 329-332 (2009).
117. Snape MD, Pollard AJ. Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect. Dis. 5, 21-30 (2005).
118. CDC. Vaccination coverage among adolescents aged 13-17 years - United States, 2007. MMWR Morb. Mortal. Wkly Rep. 57, 1100-1103 (2008).
119. Snape MD, Perrett KP, Ford KJ et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial, JAMA 299, 173-184 (2008).
120. Black S, Dull P. MenACWY-CRM, a novel quadrivalent meningococcal conjugate vaccine, is well tolerated and immunogenic in infancy through adolescence. Presented at: 26th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). Graz, Austria, 13-17 May 2008.
121. Ostergaard L, Lebacq E, Poolman J et al. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine 27, 161-168 (2009).
122. Tejedor JC, Moro M, Ruiz-Contreras J et al.; for the Spanish DTPa-HBV-IPV- 097 Study Group. Immunogenicity and reactogenicity of primary immunization with a novel combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine coadministered with a diphtheria- tetanus-acellular pertussis-hepatitis B- inactivated poliovirus vaccine at 2, 4 and 6 months. Pediatr. Infect. Dis. J. 26, 1-7 (2007).
123. Pace D, Snape M, Westcar S et al. A new combination Haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants. Pediatr. Infect. Dis. J. 26, 1057-1059 (2007).
124. Nolan T, Lambert S, Roberton D et al. A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants. Vaccine 25, 8487-8499 (2007).
125. Hodgson A, Forgor AA, Chandramohan D et al. A Phase II, randomized study on an investigational DTPw-HBV/Hib-MenAC conjugate vaccine administered to infants in Northern Ghana. PLoS ONE 3, e2159 (2008).
126. Okoko BJ, Idoko OT, Adegbola RA. Prospects and challenges with introduction of a mono-valent meningococcal conjugate vaccine in Africa. Vaccine 27, 2023-2029 (2009).
127. WHO. Improved meningitis vaccine for Africa could signal eventual end to deadly scourge. Wkly Epidemiol. Rec. 82, 222-224 (2007).
128. Finne J, Bitter-Suermann D, Goridis C, Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J. Immunol. 138, 4402-4407 (1987).
129. Bruge J, Bouveret-Le Cam N, Danve B, Rougon G, Schulz D. Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine 22, 1087-1096 (2004).
130. Bjune G, Hoiby EA, Gronnesby JK et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338, 1093-1096 (1991).
131. Sierra GV, Campa HC, Varcacel NM et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 14, 195-210 (1991).
132. de Moraes JC, Perkins BA, Camargo MC et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 340, 1074-1078 (1992).
133. Boslego J, Garcia J, Cruz C et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine 13, 821-829 (1995).
134. Bjune G. "Herd immunity" and the meningococcal vaccine trial in Norway. Lancet 340, 315 (1992).
135. O'Hallahan J, Lennon D, Oster P. The strategy to control New Zealand's epidemic of group B meningococcal disease. Pediatr. Infect. Dis. J. 23, S293-S298 (2004).
136. Oster P, Lennon D, O'Hallahan J, Mulholland K, Reid S, Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitides serogroup B disease epidemic strain. Vaccine 23, 2191-2196 (2005).
137. Kelly C, Arnold R, Galloway Y, O'Hallahan J. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am. J. Epidemiol. 166, 817-823 (2007).
138. Galloway Y, Stehr-Green P, McNicholas A, O'Hallahan J. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int. J. Epidemiol. 38, 413-418 (2009).
139. de Kleijn ED, de Groot R, Lafeber AB et al. Prevention of meningococcal serogroup B infections in children: a protein-based vaccine induces immunologic memory. J. Infect. Dis. 184, 98-102 (2001).
140. Cartwright K, Morris R, Rumke H et al. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine 17, 2612-2619 (1999).
141. de Kleijn ED, de Groot R, Labadie J et al. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age. Vaccine 18, 1456-1466 (2000).
142. Sandbu S, Feiring B, Oster P et al. Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines. Clin. Vaccine Immunol. 14, 1062-1069 (2007).
143. Boutriau D, Poolman J, Borrow R et al. Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents. Clin. Vaccine Immunol. 14, 65-73 (2007).
144. Sacchi CT, Whitney AM, Popovic T et al. Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998. J. Infect. Dis. 182, 1169-1176 (2000).
145. Peeters CC, Rumke HC, Sundermann LC et al. Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine 14, 1009-1015 (1996).
146. Rosenqvist EE, Hoiby A, Wedege E et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect. Immun. 63, 4642-4652 (1995).
147. Feavers IM, Pizza M. Meningococcal protein antigens and vaccines. Vaccine 27(Suppl. 2), B42-B50 (2009).
148. Callaghan MJ, Jolley KA, Maiden MC. Opacity-associated adhesin repertoire in hyperinvasive Neisseria meningitidis. Infect. Immun. 74, 5085-5094 (2006).
149. Rokbi B, Renauld-Mongenie G, Mignon M et al. Allelic diversity of the two transferrin binding protein B gene isotypes among a collection of Neisseria meningitidis strains representative of serogroup B disease: implication for the composition of a recombinant TbpB-based vaccine. Infect. Immun. 68, 4938-4947 (2000).
150. Madico G, Welsch JA, Lewis LA et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J. Immunol. 177, 501-510 (2006).
151. Murphy E, Andrew L, Lee KL et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J. Infect. Dis. 200, 379-389 (2009).
152. Beernink PT, Welsch JA, Harrison LH, Leipus A, Kaplan SL, Granoff DM. Prevalence of factor H-binding protein variants and NadA among meningococcal group b isolates from the United States: implications for the development of a multicomponent group B vaccine. J. Infect. Dis. 195, 1472-1479 (2007).
153. Comanducci M, Bambini S, Brunelli B et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J. Exp. Med. 195, 1445-1454 (2002).
154. Bambini S, Muzzi A, Olcen P, Rappuoli R, Pizza M, Comanducci M. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 27, 2794-2803 (2009).
155. O'Dwyer CA, Reddin K, Martin D et al. Expression of heterologous antigens in commensal Neisseria spp.: preservation of conformational epitopes with vaccine potential. Infect. Immun. 72, 6511-6518 (2004).
156. Halperin SA, Langley JM, Smith B et al. Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults. Vaccine 25, 450-457 (2007).
157. Kelly DF, Rappuoli R. Reverse vaccinology and vaccines for serogroup B Neisseria meningitidis. Adv. Exp. Med. Biol. 568, 217-223 (2005).
158. Giuliani MM, Adu-Bobie J, Comanducci M et al. A universal vaccine for serogroup B meningococcus. PNAS 103, 10834-10839 (2006).
159. Koeberling O, Giuntini S, Seubert A, Granoff DM. Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2. Clin. Vaccine Immunol. 16, 156-162 (2009).
160. Richmond P, Marshall H, Nissen MD et al. A randomized, observer-blinded, active control, Phase 1 trial of meningococcal serogroup B rLP2086 vaccine in healthy children and adolescents aged 8 to 14 years. Presented at: 16th International Pathogenic Neisseria Conference. Rotterdam, The Netherlands, 7-12 September 2008.
161. Snape MD, Dawson T, Morant A et al. Immunogenicty and reactogenicity of a novel serogroup B Neisseria meningitidis vaccine administered from 6 months of age. Presented at: 16th International Pathogenic Neisseria Conference. Rotterdam, The Netherlands, 7-12 September 2008.